Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01 This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS JIANGSU, China, June 05, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a biopharmaceutical company focused on the discovery, development, and commercialization of novel oligonucleotide...

Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RAG-17, a novel siRNA...

Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company. "I am thrilled to...